Dexcom (DXCM) stock analysis 2026: $4.82B TTM revenue up 16.2%, EPS +75.5% to $2.34, P/E 30.8x, GLP-1 drug interaction with CGM adoption, Stelo OTC launch, FreeStyle Libre competition, and analyst consensus Strong Buy with $81.64 target.
Boston Scientific (BSX) stock analysis 2026: TTM revenue $20.6B growing 17.4%, P/E 24.2x, 52-week range $52.52–$109.50, analyst target $83.47, WATCHMAN FLX growth, and EP system competitive dynamics.
Intuitive Surgical stock analysis for 2026: da Vinci 5 FDA clearance and upgrade cycle implications, razor-and-blade model economics, Ion lung biopsy platform growth, competitive threats from Medtronic Hugo and J&J Ottava, and valuation framework for growth investors.